Search Results

There are 14528 results for: content related to: Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia

  1. Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

    Clinical Pharmacology & Therapeutics

    Volume 88, Issue 5, November 2010, Pages: 676–684, E Ngaimisi, S Mugusi, O M Minzi, P Sasi, K-D Riedel, A Suda, N Ueda, M Janabi, F Mugusi, W E Haefeli, J Burhenne and E Aklillu

    Version of Record online : 29 SEP 2010, DOI: 10.1038/clpt.2010.172

  2. Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 4, April 2012, Pages: 673–684, E D Kharasch, D Whittington, D Ensign, C Hoffer, P S Bedynek, S Campbell, K Stubbert, A Crafford, A London and T Kim

    Version of Record online : 7 MAR 2012, DOI: 10.1038/clpt.2011.276

  3. You have free access to this content
    Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa

    British Journal of Clinical Pharmacology

    Volume 80, Issue 1, July 2015, Pages: 146–156, Phumla Z. Sinxadi, Paul D. Leger, Helen M. McIlleron, Peter J. Smith, Joel A. Dave, Naomi S Levitt, Gary Maartens and David W. Haas

    Version of Record online : 28 MAY 2015, DOI: 10.1111/bcp.12590

  4. Pharmacokinetic Interaction Between Voriconazole and Efavirenz at Steady State in Healthy Male Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 1, January 2008, Pages: 73–84, Mr Ping Liu, Dr Grover Foster, Mr Rober R. LaBadie, Dr Mari J. Gutierrez and Dr Amarnath Sharma

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007309703

  5. Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 3, March 2012, Pages: 475–482, V Michaud, E Ogburn, N Thong, A O Aregbe, T C Quigg, D A Flockhart and Z Desta

    Version of Record online : 8 FEB 2012, DOI: 10.1038/clpt.2011.249

  6. You have free access to this content
    Biowaiver monographs for immediate release solid oral dosage forms: Efavirenz

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 2, February 2013, Pages: 318–329, Rodrigo Cristofoletti, Anita Nair, Bertil Abrahamsson, D. W. Groot, Sabine Kopp, Peter Langguth, James E. Polli, Vinod P. Shah and Jennifer B. Dressman

    Version of Record online : 22 NOV 2012, DOI: 10.1002/jps.23380

  7. You have full text access to this OnlineOpen article
    Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

    Clinical Pharmacology & Therapeutics

    Volume 98, Issue 4, October 2015, Pages: 406–416, L Dickinson, J Amin, L Else, M Boffito, D Egan, A Owen, S Khoo, D Back, C Orrell, A Clarke, M Losso, P Phanuphak, D Carey, DA Cooper, S Emery and R Puls2, on behalf of the ENCORE1 Study Group

    Version of Record online : 14 JUL 2015, DOI: 10.1002/cpt.156

  8. Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 3, March 2012, Pages: 506–513, S Oswald, H E Meyer zu Schwabedissen, A Nassif, C Modess, Z Desta, E T Ogburn, J Mostertz, M Keiser, J Jia, A Hubeny, A Ulrich, D Runge, M Marinova, D Lütjohann, H K Kroemer and W Siegmund

    Version of Record online : 1 FEB 2012, DOI: 10.1038/clpt.2011.255

  9. You have free access to this content
    Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

    British Journal of Clinical Pharmacology

    Volume 75, Issue 4, April 2013, Pages: 997–1006, Daniel H. Johnson, Tebeb Gebretsadik, Ayumi Shintani, Gail Mayo, Edward P. Acosta, C. Michael Stein and David W. Haas

    Version of Record online : 15 MAR 2013, DOI: 10.1111/j.1365-2125.2012.04454.x

  10. You have free access to this content
    Mitochondrial (dys)function – a factor underlying the variability of efavirenz-induced hepatotoxicity?

    British Journal of Pharmacology

    Volume 172, Issue 7, April 2015, Pages: 1713–1727, M Polo, F Alegre, H A Funes, A Blas-Garcia, V M Victor, J V Esplugues and N Apostolova

    Version of Record online : 8 JAN 2015, DOI: 10.1111/bph.13018

  11. Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin

    The Journal of Clinical Pharmacology

    Volume 48, Issue 4, April 2008, Pages: 518–523, Dr Jennifer L. DiGiacinto, Dr Kirk M. Chan-Tack, Dr Sarah M. Robertson, Dr Kellie S. Reynolds and Dr Kimberly A. Struble

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008315308

  12. You have free access to this content
    Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA

    HIV Medicine

    Volume 12, Issue 2, February 2011, Pages: 97–108, HE Hsu, CE Rydzak, KL Cotich, B Wang, PE Sax, E Losina, KA Freedberg, SJ Goldie, Z Lu, RP Walensky and for the CEPAC Investigators

    Version of Record online : 17 JUN 2010, DOI: 10.1111/j.1468-1293.2010.00856.x

  13. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers

    Biopharmaceutics & Drug Disposition

    Volume 29, Issue 2, January 2008, Pages: 91–101, Qing Ma, Alan Forrest, Susan L. Rosenkranz, Michael F. Para, Kevin E. Yarasheski, Richard C. Reichman and Gene D. Morse

    Version of Record online : 27 NOV 2007, DOI: 10.1002/bdd.597

  14. Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation

    The Journal of Clinical Pharmacology

    Volume 48, Issue 9, September 2008, Pages: 1032–1040, Dr Awewura Kwara, Dr Margaret Lartey, Mr Kwamena W. Sagoe, Dr Fafa Xexemeku, Dr Ernest Kenu, Dr Joseph Oliver-Commey, Dr Vincent Boima, Mr Augustine Sagoe, Dr Isaac Boamah, Mr David J. Greenblatt and Dr Michael H. Court

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008321790

  15. Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple-Dose Administration in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 8, August 2008, Pages: 948–956, Ping Ji, Dr Bharat Damle, Dr Jingdong Xie, Dr Steve E. Unger, Dennis M. Grasela and Sanjeev Kaul

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008319792

  16. Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 1, July 2012, Pages: 103–111, H E Meyer zu Schwabedissen, S Oswald, C Bresser, A Nassif, C Modess, Z Desta, E T Ogburn, M Marinova, D Lütjohann, C Spielhagen, M Nauck, H K Kroemer and W Siegmund

    Version of Record online : 16 MAY 2012, DOI: 10.1038/clpt.2012.34

  17. You have free access to this content
    Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 65, Issue 4, April 2008, Pages: 523–530, Bharat Damle, Robert LaBadie, Penelope Crownover and Paul Glue

    Version of Record online : 20 FEB 2008, DOI: 10.1111/j.1365-2125.2007.03085.x

  18. Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

    The Journal of Clinical Pharmacology

    Volume 44, Issue 11, November 2004, Pages: 1273–1281, Niresh Hariparsad, Srikanth C. Nallani, Rucha S. Sane, Donna J. Buckley, Arthur R. Buckley and Pankaj B. Desai

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004269142

  19. Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants

    The Journal of Clinical Pharmacology

    Volume 52, Issue 8, August 2012, Pages: 1248–1254, Juki Ng, Yi-Lin Chiu, Walid Awni, Barry Bernstein, Sonja J. Causemaker and Cheri E. Klein

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011410568

  20. You have free access to this content
    Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans

    HIV Medicine

    Volume 13, Issue 4, April 2012, Pages: 193–201, S Nanzigu, J Eriksen, F Makumbi, S Lanke, M Mahindi, R Kiguba, O Beck, Q Ma, GD Morse, LL Gustafsson and P Waako

    Version of Record online : 22 NOV 2011, DOI: 10.1111/j.1468-1293.2011.00952.x